Companies › Qilu Pharmaceutical
29 active drug programs in 93 registered trials: 30 Phase 3, 29 Phase 2, 25 Phase 1, 9 Phase 4; Oncology, Immunology, Infectious disease, Other; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tafamidis Transthyretin stabiliser | TTR | Phase 4 | Transthyretin Amyloid Polyneuropathy; Transthyretin Cardiac Amyloidosis | Jan 2028 |
| Relugolix Gonadotropin-releasing hormone receptor antagonist | GNRHR | Phase 3 | Heavy Menstrual Bleeding; Cervical Mucus; Endometriosis; Recurrent Prostate Carcinoma … | Nov 2026 |
| QLC5508 B7H3-targeting antibody-drug conjugate | B7H3 | Phase 3 | Esophageal Squamous Cell Carcinoma (ESCC); Extensive-stage Small Cell Lung Cancer; Refractory or Relapsed Solid Tumors; Advanced Prostate Cancer … | Dec 2026 |
| Meropenem Bacterial penicillin-binding protein inhibitor | FTSZ | Phase 3 | Hospital-acquired Bacterial Pneumonia (HABP); Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia; MDR Bacteria; Febrile Neutropenia … | Dec 2026 |
| Pembrolizumab (QL2107) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | NSCLC; Carcinoma, Non-Small-Cell Lung; Extensive-stage Small Cell Lung Cancer; Advanced Solid Tumor | Dec 2026 |
| QLM1016 | – | Phase 3 | Schizophrenia | Dec 2026 |
| Denosumab (QL1206) Tumor necrosis factor ligand superfamily member 11 inhibitor | TNFSF11 | Phase 3 | Postmenopausal Women With Osteoporosis at High Risk of Fracture | Jan 2027 |
| QLM3003 ointment (1.5%) | – | Phase 3 | Atopic Dermatitis | Mar 2027 |
| MHB088C for Injection Antibody drug conjugate (ADC) | – | Phase 3 | Small Cell Lung Cancer Extensive Stage; Advanced/Metastatic Solid Tumors | May 2027 |
| ESG401 Estrogen receptor degrader | – | Phase 3 | Triple-Negative Breast Cancer (TNBC); Metastatic Breast Cancer | Jun 2027 |
| GM1 Monosialotetrahexosylganglioside (GM1 ganglioside) | – | Phase 3 | Chemotherapy-induced Peripheral Neuropathy (CIPN); Stroke | Jun 2027 |
| QLM3004 Ophthalmic Solution | – | Phase 3 | Myopia | Jun 2027 |
| Voclosporin (QL1074) Serine/threonine protein phosphatase 2B catalytic subunit, alpha isoform inhibitor | PPP3CA | Phase 3 | Lupus Nephritis | Jun 2027 |
| QL1706 | – | Phase 3 | Carcinoma, Non-Small-Cell Lung; Lung Cancer; Colon Cancer; Advanced Solid Tumor … | Aug 2027 |
| QLS32015 Unclear - proprietary code-named compound | – | Phase 3 | Relapsed or Refractory Multiple Myeloma | Nov 2027 |
| QL2106 injection IL-23 inhibitor | IL23A | Phase 3 | Plaque Psoriasis | Dec 2027 |
| QLS31905 anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 3 | Gastric or Gastroesophageal Junction Adenocarcinoma; Pancreatic Cancer | Sep 2028 |
| QL0911 | – | Phase 2 | Cancer Treatment-Induced Thrombocytopenia | Apr 2027 |
| QLC2519 Modified G-CSF fused to human serum albumin (HSA) with reduced G-CSF receptor affinity | CSF3R | Phase 2 | Pediatric Malignant Solid Tumor | Jun 2027 |
| QLS1304 unclear - mechanism not specified in registry text | – | Phase 1 | Advanced Malignant Tumor; Advanced ER+/HER2- Breast Cancer | Nov 2026 |
| QLH12016 Androgen receptor PROTAC | AR | Phase 1 | Advanced Prostate Cancer | Dec 2026 |
| QLC1101 KRAS G12D inhibitor | KRAS | Phase 1 | Non-small Cell Lung Cancer | Apr 2027 |
| QLS31903 | – | Phase 1 | Advanced Solid Tumors | Jun 2027 |
| QLS5212 anti-trophoblast glycoprotein (TPBG) antibody-drug conjugate | TPBG | Phase 1 | Solid Tumor Cancer | Nov 2027 |
| QLP2117 | – | Phase 1 | Advanced Solid Tumor | Dec 2027 |
| QLS2309 anti-CD70 antibody-drug conjugate | CD70 | Phase 1 | Relapsed or Refractory Hematologic Malignancies | Dec 2027 |
| QLS2319 | – | Phase 1 | Cancer Cachexia | Oct 2028 |
| Follitropin Alfa Follicle stimulating hormone receptor agonist | FSHR | Phase 1 | Infertility, Female | – |
| Meropenem-Pralubactam Beta-lactam antibiotic combined with beta-lactamase inhibitor | – | Phase 1 | Infections | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05320406 | Relugolix | Phase 2 | Biochemically Recurrent Prostate Carcinoma | Oncology | Jan 2025 |
| NCT07124468 | Meropenem-Pralubactam | Phase 1 | Infections | Infectious disease | Dec 2025 |
| NCT07096310 | Meropenem | Phase 1 | Sepsis | Infectious disease | Jan 2026 |
| NCT06864793 | Follitropin Alfa | Phase 1 | Infertility, Female | Genitourinary | Feb 2026 |
| NCT06631521 | Relugolix | Phase 1 | Prostate CA | Oncology | Jun 2026 |
| NCT07694700 | Meropenem | Phase 4 | MDR Bacteria | Other | Aug 2026 |
| NCT06671548 | Relugolix | Phase 3 | Heavy Menstrual Bleeding | Genitourinary | Nov 2026 |
| NCT06823609 | QLS1304 | Phase 1 | Advanced Malignant Tumor | Oncology | Nov 2026 |
| NCT06787183 | QL1706 | Phase 2 | Locally Advanced Rectal Cancer With Liver Metastases | Oncology | Dec 2026 |
| NCT06809530 | QL1706 | Phase 1 | Leptomeningeal Metastasis | Oncology | Dec 2026 |
| NCT07620041 | QLC5508 | Phase 1 | Refractory or Relapsed Solid Tumors | Oncology | Dec 2026 |
| NCT07198633 | QLC5508 | Phase 1 | Advanced Prostate Cancer | Oncology | Dec 2026 |
| NCT06799559 | QLM1016 | Phase 3 | Schizophrenia | Psychiatry | Dec 2026 |
| NCT07089186 | Meropenem | Phase 3 | Hospital-acquired Bacterial Pneumonia (HABP) | Infectious disease | Dec 2026 |
| NCT07198633 | QLH12016 | Phase 1 | Advanced Prostate Cancer | Oncology | Dec 2026 |
| NCT06754644 | Pembrolizumab (QL2107) | Phase 3 | NSCLC | Oncology | Dec 2026 |
| NCT07162883 | Pembrolizumab (QL2107) | Phase 3 | Carcinoma, Non-Small-Cell Lung | Oncology | Dec 2026 |
| NCT07062978 | Denosumab (QL1206) | Phase 3 | Postmenopausal Women With Osteoporosis at High Risk of Fracture | Metabolic and endocrine | Jan 2027 |
| NCT07519044 | GM1 | Phase 4 | Stroke | Neurology | Jan 2027 |
| NCT06897046 | QL1706 | Phase 2 | Non-small Cell Lung Cancer (NSCLC) | Oncology | Feb 2027 |
| NCT06880276 | QLM3003 ointment (1.5%) | Phase 3 | Atopic Dermatitis | Immunology | Mar 2027 |
| NCT06880276 | QLM3003 ointment (1.5%) | Phase 3 | Atopic Dermatitis | Immunology | Mar 2027 |
| NCT06941766 | QL1706 | Phase 1 | Intermediate Trophoblastic Tumor | Oncology | Apr 2027 |
| NCT06456528 | QL0911 | Phase 2 | Cancer Treatment-Induced Thrombocytopenia | Oncology | Apr 2027 |
| NCT06403735 | QLC1101 | Phase 1 | Non-small Cell Lung Cancer | Oncology | Apr 2027 |
| NCT07014150 | QL1706 | Phase 2 | Hepatocellular Carcinoma Resectable | Oncology | May 2027 |
| NCT07014150 | QL1706 | Phase 2 | Hepatocellular Carcinoma Resectable | Oncology | May 2027 |
| NCT06954246 | MHB088C for Injection | Phase 3 | Small Cell Lung Cancer Extensive Stage | Oncology | May 2027 |
| NCT06967103 | QL1706 | Phase 2 | Breast Cancer | Oncology | May 2027 |
| NCT07302451 | Relugolix | Phase 2 | Prostate Cancer (Adenocarcinoma) | Oncology | May 2027 |
| NCT05489523 | Tafamidis | Phase 4 | Transthyretin Cardiac Amyloidosis | Cardiovascular | May 2027 |
| NCT06151587 | QLM3004 Ophthalmic Solution | Phase 3 | Myopia | Ophthalmology | Jun 2027 |
| NCT06732323 | ESG401 | Phase 3 | Triple-Negative Breast Cancer (TNBC) | Oncology | Jun 2027 |
| NCT06406205 | Voclosporin (QL1074) | Phase 3 | Lupus Nephritis | Immunology | Jun 2027 |
| NCT06994507 | GM1 | Phase 3 | Chemotherapy-induced Peripheral Neuropathy (CIPN) | Neurology | Jun 2027 |
| NCT05823285 | QLS31903 | Phase 1 | Advanced Solid Tumors | Oncology | Jun 2027 |
| NCT07724756 | QLC2519 | Phase 2 | Pediatric Malignant Solid Tumor | Oncology | Jun 2027 |
| NCT06313970 | QL1706 | Phase 2 | Pancreatic Cancer | Oncology | Jun 2027 |
| NCT06383767 | ESG401 | Phase 3 | Metastatic Breast Cancer | Oncology | Jun 2027 |
| NCT05765500 | Relugolix | Phase 2 | Prostate Cancer | Oncology | Jul 2027 |
| NCT07102004 | MHB088C for Injection | Phase 1 | Advanced/Metastatic Solid Tumors | Oncology | Jul 2027 |
| NCT07070700 | QL1706 | Phase 2 | Intrahepatic Cholangiocarcinoma (Icc) | Oncology | Aug 2027 |
| NCT07091305 | QL1706 | Phase 2 | Limited-stage Small Cell Lung Cancer (LS-SCLC) | Oncology | Aug 2027 |
| NCT07178171 | QL1706 | Phase 1 | TNBC, Triple Negative Breast Cancer | Oncology | Aug 2027 |
| NCT07111247 | Relugolix | Phase 4 | Cervical Mucus | Other | Aug 2027 |
| NCT05487391 | QL1706 | Phase 3 | Carcinoma, Non-Small-Cell Lung | Oncology | Aug 2027 |
| NCT07180160 | QL1706 | Phase 2 | Advanced Breast Cancer | Oncology | Sep 2027 |
| NCT07467629 | QLS5212 | Phase 1 | Solid Tumor Cancer | Oncology | Nov 2027 |
| NCT07018050 | QLS32015 | Phase 2 | Relapsed or Refractory Multiple Myeloma | Oncology | Nov 2027 |
| NCT07179900 | QL1706 | Phase 2 | Hepatocellular Carcinoma | Oncology | Dec 2027 |
| NCT06911827 | Pembrolizumab (QL2107) | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2027 |
| NCT06911827 | QLP2117 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2027 |
| NCT07138209 | QLS32015 | Phase 3 | Relapsed or Refractory Multiple Myeloma | Oncology | Dec 2027 |
| NCT07173595 | QLS2309 | Phase 1 | Relapsed or Refractory Hematologic Malignancies | Oncology | Dec 2027 |
| NCT07511647 | QL2106 injection | Phase 3 | Plaque Psoriasis | Immunology | Dec 2027 |
| NCT06330805 | Relugolix | Phase 2 | Prostate Adenocarcinoma | Oncology | Dec 2027 |
| NCT06940336 | Tafamidis | Phase 4 | Transthyretin Amyloid Polyneuropathy | Neurology | Jan 2028 |
| NCT07267078 | QL1706 | Phase 2 | Biliary Tract Cancer | Oncology | Jan 2028 |
| NCT06111781 | Relugolix | Phase 2 | Prostate Cancer | Oncology | Feb 2028 |
| NCT06293677 | Meropenem | Phase 4 | Febrile Neutropenia | Oncology | Mar 2028 |
The 60 nearest readouts of 93 trials; the rest in the app.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.